Vignesh Gunasekharan

机构：National Cancer Institute, National Cancer Institute · ORCID：0000-0002-2471-8485

发表论文 87 篇 · 总被引 722 次 · h-index 13

代表论文

• AI is a viable alternative to high throughput screening: a 318-target study (2024 · Scientific Reports · 被引 128)
• Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer (2024 · Breast Cancer Research and Treatment · 被引 10)
• Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer (2024 · Breast Cancer Research and Treatment · 被引 5)
• Author Correction: AI is a viable alternative to high throughput screening: a 318-target study (2024 · Scientific Reports · 被引 2)
• Abstract 948: TRAIL inducing drug, ONC201 prevents adenocarcinoma in transgenic KRASG12V mouse lung cancer model (2026 · Cancer Research)
• Abstract 6336: Preclinical efficacy of TRAIL inducing ONC201 against carcinogen (NNK)-induced lung adenocarcinoma in A/J mouse model (2025 · Cancer Research)